Page last updated: 2024-11-07

y 26763

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Y 26763: structure given in first source; an active metabolite of Y 27152 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121878
CHEMBL ID1402866
CHEBI ID92788
SCHEMBL ID226242
MeSH IDM0200743

Synonyms (30)

Synonym
HMS3268J05 ,
BRD-K45117373-001-01-1
y-26763
NCGC00092303-01
y 26763
(+)-(3s,4r)-(n-acetyl-n-hydroxy)amino-6-cyano-3,4-dihydro-2,2-dimethyl-2h-1-benzopyran-3-ol
acetamide, n-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2h-1-benzopyran-4-yl)-n-hydroxy-, (3s-trans)-
n-[(3s,4r)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-n-hydroxyacetamide
127408-31-5
unii-q9f3xv8a6x
q9f3xv8a6x ,
n-[(3s,4r)-6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2h-1-benzopyran-4-yl]-n-hydroxyacetamide
acetamide, n-((3s,4r)-6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2h-1-benzopyran-4-yl)-n-hydroxy-
(3s,4r)-(n-acetyl-n-hydroxy)amino-6-cyano-3,4-dihydro- 2,2-dimethyl-2h-1-benzopyran-3-ol, (+)
SCHEMBL226242
AKOS022180565
CHEMBL1402866
DTXSID80155562
J-005492
n-((3s,4r)-6-cyano-3-hydroxy-2,2-dimethylchroman-4-yl)-n-hydroxyacetamide
mfcd00888284
CHEBI:92788
Q27164549
HMS3678O05
HMS3414O05
CS-0020782
MS-23927
HY-101069
CFA40831
acetamide, n-[(3s,4r)-6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2h-1-benzopyran-4-yl]-n-hydroxy-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"1 mg/kg) occurred during an 8-week repeated daily dosing to RHD and plasma renin activity, and aldosterone levels were not elevated during this period."( Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
Aoki, K; Fukunari, A; Katoh, A; Nakajima, T; Setoguchi, M; Shinagawa, K; Shinohara, T; Tahara, T; Yamanaka, T; Yaoka, O, 1992
)
0.28
" Isometric tension was measured and dose-response curves were constructed for levcromakalim (a KATP opener), Y-26763 (another KATP opener), isoprenaline and theophylline in guinea-pig isolated trachea that was challenged with ovalbumin or pretreated in vitro with either isoprenaline or the KATP openers."( Allergic responses reduce the relaxant effect of beta-agonists but not potassium channel openers in guinea-pig isolated trachea.
Dobashi, K; Houjou, S; Iizuka, K; Nakazawa, T, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1-benzopyran
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's23 (69.70)18.2507
2000's6 (18.18)29.6817
2010's2 (6.06)24.3611
2020's2 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.85 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]